公开(公告)号：US11554168B2

公开(公告)日：2023-01-17

申请号：US17008335

申请日：2020-08-31

Applicant: Vir Biotechnology, Inc. ,  Triad National Security, LLC ,  Oregon Health & Science University

Inventor： Eric Bruening ,  Klaus Frueh ,  Louis Picker ,  Bette T. M. Korber ,  James Theiler ,  Emily Marshall

IPC: C12N15/86 ,  A61K39/21 ,  A61K39/00 ,  A61K39/12

Abstract: Provided herein are HIV-1 vaccines comprising a carrier and a population episensus antigen determined using the EpiGraph approach. Also provided are HIV-1 vaccines comprising a carrier, a population episensus antigen, and a tailored antigen. Also provided are methods of designing and producing an HIV-1 vaccine for a subject comprising designing vaccine antigens to optimally cover the diversity within a geographic area using an antigen amino acid sequence generated using the EpiGraph approach, and producing said designed vaccine antigen. Also provided are methods of inducing an effector memory T cell response comprising designing the one or more EpiGraph amino acid sequences, producing a vaccine comprising the one or more EpiGraph amino acid sequences and a vector, and administering the vaccine to a subject. Further provided are methods of treating HIV-1 in a subject comprising administering an effective amount of the described HIV-1 vaccines to the subject in need thereof.

公开(公告)号：US20240384296A1

公开(公告)日：2024-11-21

申请号：US18687050

申请日：2022-08-30

Applicant: Vir Biotechnology, Inc.

Inventor： Ann M. Arvin ,  Janet L. Douglas ,  Emily Marshall ,  Herbert W. Virgin

IPC: C12N15/86 ,  A61K9/00 ,  A61K39/00 ,  A61P31/18 ,  C07K14/005

Abstract: The disclosure relates to human cytomegalovirus (HCMV) vectors for delivering heterologous antigens and immunogenic compositions comprising the same.

公开(公告)号：US20240350607A1

公开(公告)日：2024-10-24

申请号：US18687463

申请日：2022-08-30

Applicant: Vir Biotechnology, Inc.

Inventor： Ann M. Arvin ,  Julia Di Iulio ,  Janet L. Douglas ,  Emily Marshall ,  Leah B. Soriaga ,  Herbert W. Virgin

IPC: A61K39/04 ,  A61K39/00 ,  C07K14/35 ,  C12N5/0783 ,  C12N15/86

CPC classification number: A61K39/04 ,  A61K39/4611 ,  C07K14/35 ,  C12N5/0636 ,  C12N15/86 ,  A61K2039/5256 ,  C07K2319/42 ,  C12N2510/00 ,  C12N2710/16143

Abstract: The disclosure relates to tuberculosis antigens and vectors for delivering the antigens. The disclosure also relates to immunogenic compositions comprising the same, and their uses.

公开(公告)号：US20210046175A1

公开(公告)日：2021-02-18

申请号：US17008335

申请日：2020-08-31

Applicant: Vir Biotechnology, Inc. ,  Triad National Security, LLC ,  Oregon Health & Science University

Inventor： Eric Bruening ,  Klaus Frueh ,  Louis Picker ,  Bette T.M. Korber ,  James Theiler ,  Emily Marshall

IPC: A61K39/12 ,  A61K39/21 ,  C12N15/86

Abstract: Provided herein are HIV-1 vaccines comprising a carrier and a population episensus antigen determined using the EpiGraph approach. Also provided are HIV-1 vaccines comprising a carrier, a population episensus antigen, and a tailored antigen. Also provided are methods of designing and producing an HIV-1 vaccine for a subject comprising designing vaccine antigens to optimally cover the diversity within a geographic area using an antigen amino acid sequence generated using the EpiGraph approach, and producing said designed vaccine antigen. Also provided are methods of inducing an effector memory T cell response comprising designing the one or more EpiGraph amino acid sequences, producing a vaccine comprising the one or more EpiGraph amino acid sequences and a vector, and administering the vaccine to a subject. Further provided are methods of treating HIV-1 in a subject comprising administering an effective amount of the described HIV-1 vaccines to the subject in need thereof.

公开(公告)号：US20210046174A1

公开(公告)日：2021-02-18

申请号：US17008289

申请日：2020-08-31

Applicant: Vir Biotechnology, Inc. ,  Triad National Security, LLC ,  Oregon Health & Science University

Inventor： Eric Bruening ,  Klaus Frueh ,  Louis Picker ,  Bette T.M. Korber ,  James Theiler ,  Emily Marshall

IPC: A61K39/12 ,  A61K39/21 ,  C12N15/86

Abstract: Provided herein are HIV-1 vaccines comprising a carrier and a population episensus antigen determined using the EpiGraph approach. Also provided are HIV-1 vaccines comprising a carrier, a population episensus antigen, and a tailored antigen. Also provided are methods of designing and producing an HIV-1 vaccine for a subject comprising designing vaccine antigens to optimally cover the diversity within a geographic area using an antigen amino acid sequence generated using the EpiGraph approach, and producing said designed vaccine antigen. Also provided are methods of inducing an effector memory T cell response comprising designing the one or more EpiGraph amino acid sequences, producing a vaccine comprising the one or more EpiGraph amino acid sequences and a vector, and administering the vaccine to a subject. Further provided are methods of treating HIV-1 in a subject comprising administering an effective amount of the described HIV-1 vaccines to the subject in need thereof.

公开(公告)号：US11628215B2

公开(公告)日：2023-04-18

申请号：US17008289

申请日：2020-08-31

Applicant: Vir Biotechnology, Inc. ,  Triad National Security, LLC ,  Oregon Health & Science University

Inventor： Eric Bruening ,  Klaus Frueh ,  Louis Picker ,  Bette T. M. Korber ,  James Theiler ,  Emily Marshall

IPC: A61K39/21 ,  A61K39/00 ,  C12N15/86 ,  A61K39/12

Abstract: Provided herein are HIV-1 vaccines comprising a carrier and a population episensus antigen determined using the EpiGraph approach. Also provided are HIV-1 vaccines comprising a carrier, a population episensus antigen, and a tailored antigen. Also provided are methods of designing and producing an HIV-1 vaccine for a subject comprising designing vaccine antigens to optimally cover the diversity within a geographic area using an antigen amino acid sequence generated using the EpiGraph approach, and producing said designed vaccine antigen. Also provided are methods of inducing an effector memory T cell response comprising designing the one or more EpiGraph amino acid sequences, producing a vaccine comprising the one or more EpiGraph amino acid sequences and a vector, and administering the vaccine to a subject. Further provided are methods of treating HIV-1 in a subject comprising administering an effective amount of the described HIV-1 vaccines to the subject in need thereof.

公开(公告)号：US10894078B2

公开(公告)日：2021-01-19

申请号：US15516491

申请日：2015-10-05

Applicant: Vir Biotechnology, Inc. ,  Triad National Security, LLC ,  Oregon Health & Science University

Inventor： Eric Bruening ,  Klaus Frueh ,  Louis Picker ,  Bette T. M. Korber ,  James Theiler ,  Emily Marshall

IPC: A61K39/12 ,  C12N15/86 ,  A61K39/21 ,  A61K39/00

Abstract: Provided herein are HIV-1 vaccines comprising a carrier and a population episensus antigen determined using the EpiGraph approach. Also provided are HIV-1 vaccines comprising a carrier, a population episensus antigen, and a tailored antigen. Also provided are methods of designing and producing an HIV-1 vaccine for a subject comprising designing vaccine antigens to optimally cover the diversity within a geographic area using an antigen amino acid sequence generated using the EpiGraph approach, and producing said designed vaccine antigen. Also provided are methods of inducing an effector memory T cell response comprising designing the one or more EpiGraph amino acid sequences, producing a vaccine comprising the one or more EpiGraph amino acid sequences and a vector, and administering the vaccine to a subject. Further provided are methods of treating HIV-1 in a subject comprising administering an effective amount of the described HIV-1 vaccines to the subject in need thereof.